Tuesday - November 26, 2024
CVS Caremark Accelerates Biosimilars Adoption Through Formulary Changes
January 05, 2024
WOONSOCKET, Rhode Island, Jan. 5 -- CVS Health issued the following news release on Jan. 4, 2024:

Today CVS Caremark(R), a CVS Health(R) (NYSE: CVS) company, announced the continuation of its efforts to expand adoption of biosimilars. Effective April 1, 2024, Humira(R) will be removed from our major national commercial template formularies and Humira biosimilars will be covered. Humira will continue to be an option for its customers with Choice and Standard Opt Out commercial formul . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products